This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.

Expert opinions in R/R HL
Practical support for healthcare professionals
Publications

The below clinical papers can be requested from Takeda Medical Information

Request clinical papers

R/R HL Pre-ASCT

Eyre et al. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin (BV) in relapsed, refractory classical Hodgkin lymphoma (R/R HL) in the transplant naïve setting. British Journal of Haematology. 2017; doi:10.1111/bjh.14898

R/R HL Post-ASCT

Chen R, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016; 128 (12): 1562-6

Younes A, et al. Results of a Pivotal Phase II Study of brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol. 2012; 30: 2183-9

R/R HL & R/R sALCL Reuse

Bartlett NL, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Haem Onc. 2014; 7 (24): 1-8

R/R HL Consolidation

Moskowitz CH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385: 1853-62

R/R sALCL

Pro B, et al. Brentuximab vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. J Clin Oncol. 2012; 30 (18): 2190-6

Pro B, et al. Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Presented at ASH 2016. Abstract 4144

CTCL after at least 1 prior systemic therapy

Prince HM et al. Brentuximab vedotin of physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017; 390 (10094): 555-566

Request clinical papers

Patient support materials
patient guide

ADCETRIS - Your treatment booklet

Takeda Oncology has developed this booklet providing information for patients who have been prescribed ADCETRIS

Order free printed copy
Download

Adcetris Nurse PN

Peripheral Neuropathy Leaflet

A leaflet highlighting the symptoms that may indicate the presence of peripheral neuropathy.

Order free printed copy
Download

Adcetris Nurse PN poster

Peripheral Neuropathy Poster

A poster highlighting the symptoms that may indicate the presence of peripheral neuropathy.

Order free printed copy
Download

management tracker

Peripheral Neuropathy Tracker

A diary for patients to help them track any symptoms and feelings of neuropathy.

Order free printed copy
Download

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.